Baird Medical Investment Holdings Ltd BDMD
NasdaqSmall CapHealthcare
13F Pro quality score
Rank #2,555 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reading the latest SEC filing…
13F Pro quality score
Rank #2,555 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reported revenue, net income and operating margin by fiscal year, from Baird Medical Investment Holdings Ltd's annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2025 | 20-F | $22.5M | $-27.3M | -113.7% |
| FY 2024 | 20-F | $37.0M | $12.5M | 41.3% |
| FY 2023 | 20-F | $31.5M | $10.5M | 37.7% |
| FY 2022 | 20-F | $35.1M | $12.8M | 38.9% |
Baird Medical Investment Holdings Ltd (BDMD) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BDMD at 27.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,555 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), Baird Medical Investment Holdings Ltd reports quarterly revenue of $22.5M, net income of $-27.3M, an operating margin of -113.7%. BDMD trades on the Nasdaq exchange and files with the SEC under CIK 1982444. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BDMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Baird Medical Investment Holdings Ltd directly from SEC EDGAR.